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step-wise Cox multivariate analyses.
Conclusions: Despite a higher prevalence in AA, ECG strain may not provide the same
degree of risk stratification in AA as in non-AA patients.
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888-4 Angiotensin-Converting Enzyme Inhibitors Are 
Comparable to Angiotensin II Receptor Blockers in the 
Primary Prevention of Myocardial Infarction in 
Hypertensive Patients
Jefferson T. Baer, William H. Sauer, Jesse A. Berlin, Stephen E. Kimmel, University of 
Pennsylvania, Philadelphia, PA
Background: There has recently been a growing interest in the relative merits of Angio-
tensin Converting Enzyme (ACE) Inhibitors versus Angiotensin II Receptor Blockers
(ARBs) in the prevention of cardiovascular events. However, studies comparing the two
are lacking, with no studies to our knowledge directly comparing outcomes in hyperten-
sive patients. For this reason we sought to compare ACE Inhibitors with ARBs in the pre-
vention of first nonfatal myocardial infarction (MI) among hypertensive patients.
Methods: The data were obtained from two case-control studies of first MI, ages 30
through 75, coming from 68 hospitals in an eight county region during a 6 year period.
Cases were patients hospitalized with a first nonfatal MI, and controls were randomly
selected from the same geographic area. Detailed information regarding cardiac risk fac-
tors and current medications was collected via telephone interviews. Patients with con-
gestive heart failure were excluded. Multivariable logistic regression was used to adjust
for age, sex, race, cigarette smoking, history of coronary disease, family history, diabetes
mellitus, hyperlipidemia, body mass index, physical activity and duration of hypertension.
Adjustment for socioeconomic and other clinical variables did not alter the findings.
Results: 386 cases (20.7% were ARB users) and 969 controls (28.0% were ARB users)
were interviewed. There was an inverse association between ARB use and MI in the
unadjusted model with an odds ratio (OR) of 0.67 and a 95% confidence interval (CI) of
0.51-0.89. However, after adjusting for confounding, there was no difference in risk of MI
between ACE Inhibitor and ARB users (OR 1.0, 95% CI: 0.69-1.59). There were no sub-
groups of patients taking ACE Inhibitors that were at increased risk of MI when compared
to ARB users.
Conclusions: Our investigation shows that ARBs and ACE Inhibitors appear to have
comparable effects on the risk of MI when used to treat hypertensive patients without
known heart failure.
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888-5 Effect of Cardiovascular Disease Risk Factors on 
Ambulatory Blood Pressure Profile in Obesity
Otelio S. Randall, John Kwagyan, Abid Maqbool, Shichen Xu, Lien Diep, Zhenqui Huang, 
Howard University College of Medicine, Washington, DC
BACKGROUND: Ambulatory blood pressure (ABP) monitoring has been linked to organ
damage and cardiovascular events. We examined the effect of different cardiovascular
disease (CVD) risk factors on ABP in obesity.
METHODS: We studied 215 obese African Americans (88% female, with average BMI of
43 kg/m2) who enrolled in a diet-exercise program of weight reduction at Howard Univer-
sity General Clinical Research Center. Dyslipidemia was present in 36% of the patients,
hypertension in 66% and diabetes mellitus in 24%. We classified the patients as: normo-
tensives with no other risk factor, (Group I), normotensives with other risk factor (Group
II), hypertensives with no other risk factor (Group III) and hypertensives with other risk
factor (Group IV). Blood pressure and heart rate were obtained using an oscillometric
automatic recorder set to take readings every 30 min for 24 hrs. Pulse pressure (PP) is
the difference of systolic BP (SBP) and diastolic BP (DBP). Daytime BP was defined as
the average readings from 6AM -10PM and nighttime, from 10PM - 6AM. Nondippers
exhibited a nocturnal fall in mean blood pressure (MBP) of less than 10%. The average
BP and heart rate as well as the rate of nondipping were compared.
RESULTS: Results are tabulated. While there was a progressive increase in ABP and PP
from Group I to Group IV, HR and nondipping rate did not vary significantly.
CONCLUSION: In this obese population, the other CVD risk factors did not have addi-
tional effect on nondipping, a marker of target organ damage and CV events.
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888-6 Differential Effects of Selective COX-2 Inhibitors on 
Endothelial Function in Salt-induced Hypertension
Matthias Hermann, Giovanni Camici, Jens P. Hellermann, Joachim Thiery, Steffen Gay, 
Thomas F. Luscher, Frank Ruschitzka, University Hospital Zurich, Zurich, Switzerland
Background: In view of the ongoing controversy of potential differences in cardiovascu-
lar safety of selective COX-2 inhibitors (coxibs), we compared the effects of two different
coxibs and a traditional NSAID on endothelial dysfunction, a well established surrogate of
cardiovascular disease, in salt-induced hypertension.
Methods and Results: Salt-sensitive (DS) and salt-resistant (DR) Dahl rats were treated
with a high-sodium diet (4% NaCl) for 56 days. From days 35 to 56, diclofenac (6 mg/kg/
d; DS-NaCl-dic), rofecoxib (2 mg/kg/d; DS-NaCl-rof), celecoxib (25 mg/kg/d; DS-NaCl-
cel) or placebo (DS-NaCl-pla) were added to the chow. Systolic blood pressure, eNOS
and protein expression, plasma levels of prostaglandins, isoprostanes and inflammatory
cytokines were studied and vascular reactivity of aortic rings was assessed. Blood pres-
sure increased with sodium diet in the DS-groups which was more pronounced after
diclofenac and rofecoxib treatment (p<0.005 vs DS-NaCl-pla), but slightly blunted by
celecoxib (p<0.001 vs DS-NaCl-pla). Sodium diet reduced NO-mediated endothelium-
dependent relaxations to acetylcholine (ACh, 10-10-10-5 mol/L) in untreated hypertensive
rats (p<0.0001 vs DR-NaCl-pla). Relaxation to ACh improved after celecoxib (p<0.005 vs
DS-NaCl-pla and DS-NaCl-rof), but remained unchanged after rofecoxib and diclofenac
treatment. Vasoconstriction after NOS inhibition with L-NAME (10-4 mol/L) was blunted in
DS rats (p<0.05 vs DR-NaCl-pla), normalized by celecoxib, but not affected by rofecoxib
or diclofenac. Protein expression of eNOS was decreased in DS rats with a trend for
increased eNOS levels in the DS-NaCl-cel group (97.8±25.6 vs 54.8±2.8 %. Indicators of
oxidative stress, 8-isoprostane levels, were elevated in untreated DS rats on 4% NaCl
(6.55±0.58 vs 3.65±1.05 ng/ml, p<0.05) and normalized by celecoxib only (4.29±0.58 ng/
ml). Plasma levels of prostaglandins did not change during sodium diet or any treatment.
Conclusion: These data show that celecoxib, but not rofecoxib or diclofenac, improves
endothelial dysfunction and reduces oxidative stress, thus pointing to differential effects
of coxibs in salt-sensitive hypertension.
Outcome According to Race and ECG Strain
Outcome Events African Americans Caucasians and Others
5-Year Event Rates Multivariate Cox Analyses 5-Year Event Rates Multivariate Cox Analyses
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Composite 
Endpoint
14.8 18.4 0.792 0.52 0.471 ----- ---- 11.0 21.4 <0.0001 11.73 0.001 1.39 1.15-
1.68
Cardiovascular 
Mortality
8.4 7.7 0.998 0.34 0.558 ----- ---- 4.1 9.4 <0.0001 12.85 <0.001 1.69 1.28-
2.23
Myocardial 
Infarction
2.4 8.9 0.035 4.86 0.027 3.05 1.13-
8.22
4.0 8.0 <0.0001 6.07 0.014 1.47 1.08-
1.99
Stroke 7.6 7.0 0.622 1.25 0.264 ----- ---- 5.7 10.7 <0.0001 6.30 0.012 1.41 1.08-
1.85
All-Cause 
Mortality
14.4 18.3 0.530 0.09 0.759 ----- ---- 8.1 14.0 <0.0001 4.87 0.027 1.29 1.03-
1.62
Comparison of Ambulatory Blood Pressure and Heart Rate
Characteristic Group I (n=36) Group II (n=41) Group III (n=71) Group IV (n=67)
SBP/DBP/MBP
(mmHg)
24- hour 122/74/90 125/76/92 132/81/98 133/80/98
Daytime 123/76/92 126/79/95 134/84/101 135/84/101
Nighttime 119/69/86 123/71/89 127/76/93 130/76/94
Nondipping rate 0.64 0.61 0.57 0.61
PP(mmHg)/HR(bpm)
24-hours 48/84 49/83 50/78 53/81
Daytime 47/86 47/86 50/80 52/83
Nighttime 50/79 52/79 51/77 54/76
